A number of firms have modified their ratings and price targets on shares of TearLab Corp (NASDAQ: TEAR) recently:

  • 3/16/2017 – TearLab Corp was upgraded by analysts at Zacks Investment Research from a “sell” rating to a “hold” rating. According to Zacks, “TearLab Corporation is an ophthalmic device company developing and commercializing novel, lab-on-a-chip technologies that enable eye care practitioners to test for highly sensitive and specific biomarkers in tears at the point-of-care. The Company is commercializing a proprietary in vitro diagnostic tear testing platform, the TearLabTM Osmolarity System, which is capable of accurately and rapidly measuring biomarkers in tears at the point-of-care. The TearLabTM System requires nanoliters of tears for testing, potentially reducing collection time and simplifying the tear collection process. TearLab Corporation, formerly known as OccuLogix Inc., is headquartered in San Diego, California. “
  • 3/12/2017 – TearLab Corp was given a new $12.00 price target on by analysts at HC Wainwright. They now have a “buy” rating on the stock.
  • 3/11/2017 – TearLab Corp was given a new $6.00 price target on by analysts at Craig Hallum. They now have a “buy” rating on the stock.
  • 3/11/2017 – TearLab Corp was downgraded by analysts at Feltl & Co. from a “strong-buy” rating to a “buy” rating. They now have a $9.00 price target on the stock.
  • 3/10/2017 – TearLab Corp had its “buy” rating reaffirmed by analysts at Rodman & Renshaw. They now have a $12.00 price target on the stock.
  • 3/8/2017 – TearLab Corp was downgraded by analysts at Zacks Investment Research from a “hold” rating to a “sell” rating. According to Zacks, “TearLab Corporation is an ophthalmic device company developing and commercializing novel, lab-on-a-chip technologies that enable eye care practitioners to test for highly sensitive and specific biomarkers in tears at the point-of-care. The Company is commercializing a proprietary in vitro diagnostic tear testing platform, the TearLabTM Osmolarity System, which is capable of accurately and rapidly measuring biomarkers in tears at the point-of-care. The TearLabTM System requires nanoliters of tears for testing, potentially reducing collection time and simplifying the tear collection process. TearLab Corporation, formerly known as OccuLogix Inc., is headquartered in San Diego, California. “

TearLab Corp (NASDAQ:TEAR) opened at 3.18 on Tuesday. TearLab Corp has a one year low of $2.95 and a one year high of $9.10. The firm’s 50 day moving average price is $5.05 and its 200-day moving average price is $5.79. The company’s market capitalization is $17.07 million.

TearLab Corp (NASDAQ:TEAR) last posted its earnings results on Thursday, March 9th. The company reported ($0.81) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.90) by $0.09. The business had revenue of $7.12 million for the quarter, compared to analyst estimates of $7.71 million. The firm’s revenue was up 4.9% compared to the same quarter last year. During the same period in the previous year, the firm posted ($0.26) earnings per share. Equities analysts forecast that TearLab Corp will post ($2.62) earnings per share for the current fiscal year.

This article was originally published by and is the sole property of American Banking News. If you happen to be reading this article on another website, it was stolen and illegally republished in violation of U.S. and International copyright law. The original version of this story can be read at https://www.americanbankingnews.com/2017/03/21/investment-analysts-recent-ratings-updates-for-tearlab-corp-tear.html

TearLab Corporation is an in-vitro diagnostic company. The Company has commercialized a tear testing platform, the TearLab Osmolarity System, which enables eye care practitioners to test for sensitive and specific biomarkers using nanoliters of tear film at the point-of-care. The Company, through its subsidiary TearLab Research, Inc, develops technologies to enable eye care practitioners to test a range of biomarkers (chemistries, metabolites, genes and proteins) at the point-of-care.

5 Day Chart for NASDAQ:TEAR

Receive News & Ratings for TearLab Corp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TearLab Corp and related companies with MarketBeat.com's FREE daily email newsletter.